Solaris Pharma

About Solaris Pharma

Established in 2014, Solaris Pharma Corporation is a specialty pharmaceutical company operating from Bridgewater, New Jersey. The company focuses on developing and commercializing generic and specialty dermatological drugs, particularly those with high barriers to entry due to manufacturing complexities. Solaris Pharma's business model centers on identifying niche pharmaceutical products, managing their development through the regulatory process, and bringing them to market. The company generates revenue through the sale of these pharmaceutical products.

The firm was founded by Lakshmi Raghavan, with Shalin Jani currently serving as President and CEO. Mr. Jani has over two decades of experience in the pharmaceutical sector, having held roles in operations, R&D, and regulatory affairs at major companies like Teva, Sandoz, and Pfizer. His background includes a Master's degree in Cell and Developmental Biology and a Bachelor's in Molecular Biology and Biochemistry from Rutgers University.

Solaris Pharma has successfully brought several products to market. A significant achievement was receiving FDA approval in August 2021 for the first generic version of Clindagel®, a topical gel for which U.S. annual sales were approximately $31 million at the time. The company has also received approvals for other products, including Tazarotene Gel and Estradiol Gel, the latter of which was granted a 180-day Competitive Generic Therapy exclusivity period. Its product pipeline targets a range of conditions such as acne, psoriasis, atopic dermatitis, and rosacea. The company has secured over $23 million in funding to support its development and commercialization efforts.